NVTIA® Ergothioneine for Healthy Aging and Skin Health

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Healthy Aging, Skin Aging, Oxidative Stress

In brief

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks. The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.

Key facts

Study ID

NCT07750002

Run by

EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION

People needed

50

Starts

2026-08-15

Expected to finish

2027-04-08

Last updated by the study team

2026-08-06

Who can join

Age: 35 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must meet all of the following criteria:
• Male or female adults aged 35 to 55 years.
• Generally healthy as determined by medical history, physical examination, and screening assessments.
• Body Mass Index (BMI) between 18.5 and 29.9 kg/m².
• Willing and able to provide written informed consent.
• Willing to maintain their usual diet, physical activity, and lifestyle throughout the study period.
• Willing to avoid the use of other antioxidant, anti-aging, or nutritional supplements during the study period unless approved by the investigator.
• Able and willing to comply with all study procedures and scheduled visits.

You may not qualify if…

• Participants meeting any of the following criteria will be excluded:
• History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or psychiatric disease.
• Current diagnosis of diabetes mellitus requiring medication.
• Active inflammatory or autoimmune disease.
• History of malignant disease within the previous five years.
• Pregnancy, breastfeeding, or planning pregnancy during the study period.
• Known allergy or hypersensitivity to ergothioneine or any ingredient of the study product.
• Use of antioxidant supplements, anti-aging supplements, or investigational products within 30 days before enrollment.
• Current smoker or history of heavy alcohol consumption.
• Participation in another clinical trial within the previous 30 days.
• Any medical condition or laboratory abnormality that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.

Where it is running

• Dhaka Central International Medical College & Hospital — Dhaka, Bangladesh (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.